Our P5 Conjugation Technology allows to rapidly generate ultra-stable ADCs with antibody-like biophysical properties and chemical flexibility providing us with the opportunity to develop truly differentiated ADCs
Leveraging the P5 technology, our proprietary Tubutecan Platform enables stable, high DAR 8 conjugation of potent topoisomerase-I inhibitors with optimized on-target delivery and reduced off-target toxicity – without compromising ADC properties.
Our Alco5 Platform enables stable antibody conjugation of previously inaccessible payload classes, including various cytotoxins and protein degraders – unlocking novel MoAs while preserving favorable ADC properties properties.
Next generation Cystein conjugation chemistry/platform.
Simple incorporation of the P5 handle followed by an extremely efficient, highly reproducible antibody conjugation process yields homogenous and hydrophilic high DAR ADCs.
P5 enables superior linker stability in serum compared to standard maleimide-based linker systems.
P5 prevents undesired Linker-Payload transfer to endogenous serum proteins. A mechanism known for standard maleimide-based linker systems.
The Tubutecan linker-payload technology is based on ethynylphosphonamidates (P5 conjugation chemistry), a protease cleavage site and exatecan, a potent topoisomerase 1 (TOP1) inhibitor.
The Tubutecan Linker-payload system, delivering Exatecan, outperforms approved Top1-Inhibitor based ADCs in linker stability in serum. Enhertu and Trodelvy rapidly loosing payload over time in serum, whereas the P5 linker is fully stable.
The Tubutecan platform doubles the Exatecan exposure of the tumor compared to platforms using other linker systems. While other linker systems expose healthy liver tissue to Exatecan, no Exatecan is detected in the liver for Tubutecan based ADCs.
Higher tumor exposure to Exatecan directly translates to higher efficay compared to approved ADCs based on TOP1 inhibitors. The technology is characterized by a durable anti-tumor effect in preclinical models.
Alco5 enables stable conjugation and efficient intratumoral release of any hydroxy-containing payload.
Current linker technology for -OH is limited by insufficient linker stability. Alco5 is able to fix this and enables stable conjugation of SN38, leading to superior in vivo efficacy compared to common SN38 based linker-payloads as in Trodelvy.
Alco5 unlocks novel payloads via unprecendeted delivery of OH-containing drugs. The amount of dosed payload can thereby be drastically lowered.
P5-Alco5 enable the full potential of degraders. Our DACs combine high DAR, superior biophysical properties and optimal in vivo efficacy and PK.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information